Research programme: BACE1 protein inhibitors - The Genetics Company
Alternative Names: BACE inhibitorsLatest Information Update: 20 Sep 2018
At a glance
- Originator The Genetics Company
- Class Small molecules
- Mechanism of Action BACE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 07 Jan 2011 Discontinued - Preclinical for Alzheimer's disease in Switzerland (PO)
- 30 Mar 2006 This programme is still in active development for Alzheimer's disease
- 30 Mar 2004 Genetics Company and Morphochem have entered into a collaborative agreement for this programme in Alzheimer's disease